Pipeline

MicroCures has built a broad pipeline of novel therapeutic programs based on the company’s proprietary cell migration modulation platform.

The company’s cell movement acceleration programs are focused on excisional wound repair, dermal burn repair, corneal burn repair and cavernous nerve repair/regeneration, among others. Earlier-stage cell movement deceleration programs are being developed to combat cancer metastases and fibrosis.

IndicationStatusHighlight
MCR- 231 Neurotrophic Keratitis/Corneal Burn WoundsLead indication, Planned IND submission in 2023, Phase 1 trial pending INDPreclinical studies demonstrated significantly improved tissue repair, nerve repair, and ocular functionread more »
MCR- 420 Cavernous Nerve RepairPreclinical studies ongoingPreclinical studies demonstrated significantly improved erectile responseread more »
MCR-033 Central Nerve/ Spinal Cord RegenerationPreclinical studies ongoingPreclinical studies demonstrated significantly improved movement and functionread more »
MCR 111- Dermal damage: excision, burn, and abrasionPlanned IND filing and initiation of Phase 1 trials in 2024Preclinical studies demonstrated significantly improved speed and quality of tissue repairread more »
Cardiac RepairPreclinical studies ongoingPreclinical studies demonstrated significantly improved tissue repair and cardiac functionread more »